“Update at ASH in four Hemophilia A patients raises new questions on variability of factor VIII expression levels associated with SPK-8011’s treatment.”,” Cantor Fitzgerald’s analyst wrote.
A number of other research analysts have also commented on ONCE. Evercore ISI started coverage on Spark Therapeutics in a report on Wednesday, August 16th. They set an in-line rating and a $83.00 price target for the company. BidaskClub upgraded Spark Therapeutics from a hold rating to a buy rating in a report on Saturday, August 26th. Barclays started coverage on Spark Therapeutics in a report on Wednesday, September 6th. They set an overweight rating and a $104.00 price target for the company. Royal Bank of Canada started coverage on Spark Therapeutics in a report on Thursday, September 14th. They set an outperform rating and a $100.00 price target for the company. Finally, SunTrust Banks reiterated a buy rating and set a $95.00 price target (up from $85.00) on shares of Spark Therapeutics in a report on Monday, September 25th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and fifteen have given a buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $76.19.
Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) EPS for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.11). Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The business had revenue of $1.90 million for the quarter, compared to analyst estimates of $1.40 million. During the same quarter last year, the firm earned ($1.07) earnings per share. The firm’s quarterly revenue was up 45.8% compared to the same quarter last year. equities research analysts anticipate that Spark Therapeutics will post -7.6 EPS for the current year.
In other Spark Therapeutics news, Director Hospital Of Philade Children’s sold 1,000,000 shares of the company’s stock in a transaction on Thursday, September 21st. The stock was sold at an average price of $84.63, for a total value of $84,630,000.00. Following the sale, the director now directly owns 3,928,707 shares in the company, valued at $332,486,473.41. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Stephen W. Webster sold 10,000 shares of the company’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $70.14, for a total value of $701,400.00. Following the completion of the sale, the chief financial officer now owns 12,500 shares in the company, valued at $876,750. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,068,809 shares of company stock worth $89,809,385. 7.30% of the stock is currently owned by company insiders.
A number of large investors have recently made changes to their positions in ONCE. Teachers Advisors LLC grew its position in Spark Therapeutics by 1.9% in the first quarter. Teachers Advisors LLC now owns 34,534 shares of the biotechnology company’s stock valued at $1,842,000 after acquiring an additional 650 shares during the period. Russell Investments Group Ltd. grew its position in Spark Therapeutics by 81.6% in the second quarter. Russell Investments Group Ltd. now owns 25,228 shares of the biotechnology company’s stock valued at $1,507,000 after acquiring an additional 11,335 shares during the period. Schwab Charles Investment Management Inc. grew its position in Spark Therapeutics by 8.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 94,920 shares of the biotechnology company’s stock valued at $5,671,000 after acquiring an additional 7,169 shares during the period. DekaBank Deutsche Girozentrale bought a new stake in Spark Therapeutics in the second quarter valued at $829,000. Finally, Rhumbline Advisers grew its position in Spark Therapeutics by 16.0% in the second quarter. Rhumbline Advisers now owns 26,278 shares of the biotechnology company’s stock valued at $1,570,000 after acquiring an additional 3,626 shares during the period. Hedge funds and other institutional investors own 94.94% of the company’s stock.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.